Showing all 2 results
Ondansetron Orally Disintegrating Tablets
FreeProduct Composition & Available Formats
We supply Ondansetron ODT in the two primary compendial configurations required to support initial introductory pediatric dosing up to high-potency surgical and oncological maintenance regimens.
Active Ingredient Monograph Available Strengths Formulation Delivery Matrix Primary Clinical Application Ondansetron Base / Hydrochloride USP / BP / IP 4 mg Fast-Dispersing Hydrophilic Matrix (ODT) Pediatric & General Antiemetic: First-line baseline dosing for acute gastroenteritis, pediatric oncology protocols, and mild post-operative nausea. Ondansetron Base / Hydrochloride USP / BP / IP 8 mg Fast-Dispersing Hydrophilic Matrix (ODT) High-Potency Emetic Control: Advanced strength engineered for highly emetogenic chemotherapy cycles, abdominal radiation protocols, and immediate post-surgical recovery fields. Ondansetron Tablet
FreeProduct Composition & Available Strengths
We supply this critical supportive therapeutic in standard, internationally recognized strengths designed for exact preventative and rescue dosing.
Active Ingredient Available Strengths Primary Clinical Target Ondansetron HCl IP / BP / USP 4 mg Standard Prophylaxis: For moderate emetogenic chemotherapy, general post-operative rescue, and pediatric care. Ondansetron HCl IP / BP / USP 8 mg High-Potency Protection: For highly emetogenic cisplatin-based cancer regimens and severe surgical recovery.
